v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Revenues | ||||
| Services | $ 0 | $ 161,778 | $ 58,949 | $ 277,254 |
| Product | 398,657 | 244,910 | 1,324,784 | 375,819 |
| Total Revenues | 398,657 | 406,688 | 1,383,733 | 653,073 |
| Operating Expenses | ||||
| Research and development | 1,800,656 | 2,720,207 | 4,652,907 | 5,327,321 |
| General and administrative | 2,205,471 | 2,940,754 | 4,858,283 | 5,184,116 |
| Sales and marketing | 548,513 | 1,043,534 | 1,400,214 | 1,960,833 |
| Total Operating Expenses | 4,554,640 | 6,704,495 | 10,911,404 | 12,472,270 |
| Operating Loss | (4,155,983) | (6,297,807) | (9,527,671) | (11,819,197) |
| Other Income (Expenses) | ||||
| Grant income (loss) | (45,914) | 75,991 | 74,617 | 197,227 |
| Gain on disposal of fixed assets | 341 | 330 | 2,101 | 330 |
| Interest income | 163 | 160 | 179 | 318 |
| Interest expense | (740,388) | (123,356) | (866,230) | (220,025) |
| Amortization of debt discount | (405,068) | (325,305) | (855,202) | (325,305) |
| Gain (loss) on change in fair value of derivative liability | (1,374,076) | 418,681 | (1,277,758) | 418,681 |
| Gain (loss) on change in fair value of warrant liability | 1,162 | (62,764) | 14,578 | (42,726) |
| Loss on extinguishment of debt | (595,500) | 0 | (1,583,434) | 0 |
| Total Other Income (Expenses) | (3,159,280) | (16,263) | (4,491,149) | 28,500 |
| Net Loss | (7,315,263) | (6,314,070) | (14,018,820) | (11,790,697) |
| Net Loss Attributable to Non-Controlling Interest | (10,784) | 29,992 | 27,999 | 82,860 |
| Net Loss Attributable to VolitionRx Limited Stockholders | (7,326,047) | (6,284,078) | (13,990,821) | (11,707,837) |
| Other Comprehensive Income (Loss) | ||||
| Foreign currency translation adjustments | (72,313) | 575,996 | (206,620) | 829,925 |
| Net Comprehensive Loss | (7,242,950) | (6,890,066) | (13,812,200) | (12,620,622) |
| Net Loss Attributable to VolitionRx Limited Stockholders | (7,326,047) | (6,284,078) | (13,990,821) | (11,707,837) |
| Deemed dividend - down round provision in warrants | (460,100) | 0 | (460,100) | 0 |
| Net Loss Attributable to Common Stockholders | $ (7,786,147) | $ (6,890,066) | $ (14,450,921) | $ (12,620,622) |
| Net Loss Per Share - Basic and Diluted Attributable to VolitionRx Limited | $ (0.85) | $ (1.22) | $ (1.80) | $ (2.35) |
| Weighted Average Shares Outstanding - Basic and Diluted | 9,154,815 | 5,132,705 | 8,018,292 | 4,980,599 |
| X | ||||||||||
- Definition Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the fair value of derivatives recognized in the income statement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of interest income earned from interest bearing assets classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Aggregate amount of net income allocated to limited partners. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|